利用生物标志物个体化抗菌治疗疗程:一篇叙述性综述
该叙述性综述回顾了随机对照试验、观察性研究和荟萃分析,评估生物标志物指导抗菌治疗疗程决策的效果。降钙素原指导策略有助于个体化并常缩短抗菌治疗疗程,尤其在疑似呼吸道感染住院患者和重症监护室疑似呼吸道感染或脓毒症患者中;其他生物标志物的影响尚不明确,需进一步研究。
要点
- 降钙素原指导策略有助于个体化并常缩短抗菌治疗疗程,尤其在呼吸道感染住院患者中。
- C反应蛋白可能有助于早期停用抗菌治疗,但数据有限。
- 血液学生物标志物个体间变异大,受药物和非感染性疾病影响,可靠性较低。
核心结论
- 研究表明,降钙素原指导策略如使用得当,可帮助临床医生个体化并常缩短抗菌治疗疗程,尤其在呼吸道感染住院患者和重症监护室疑似呼吸道感染或脓毒症患者中。
- 其他生物标志物的影响尚不明确,需进一步研究。
研究设计与样本
- 叙述性综述,回顾了评估生物标志物指导抗菌治疗疗程决策及其对治疗时长影响的随机对照试验、观察性研究和荟萃分析。
主要发现
- 多项随机对照试验和真实世界观察性研究显示,降钙素原指导策略可帮助临床医生个体化抗菌治疗疗程。
- 在疑似呼吸道感染的住院非危重患者中,使用降钙素原截断值<0.25 μg/L时,降钙素原指导策略可帮助个体化抗菌治疗疗程。
- 在呼吸道感染或未分化脓毒症危重患者中,使用降钙素原截断值<0.5 μg/L或峰值水平下降≥80%时,降钙素原指导策略可帮助个体化抗菌治疗疗程。
- C反应蛋白是一种非特异性炎症标志物,也可能有助于早期停用抗菌治疗,但数据有限。
- 血液学生物标志物易出现个体间变异,常受药物和非感染性疾病影响,使其在抗菌治疗疗程决策中的可靠性较低。
临床怎么用
- 降钙素原指导策略如使用得当,可帮助临床医生个体化并常缩短抗菌治疗疗程,尤其在呼吸道感染住院患者和重症监护室疑似呼吸道感染或脓毒症患者中。
- 其他生物标志物的影响尚不明确,需进一步研究。
局限性
- C反应蛋白相关数据有限。
- 血液学生物标志物易出现个体间变异,常受药物和非感染性疾病影响,使其在抗菌治疗疗程决策中的可靠性较低。
- 新型生物标志物需临床研究确定其是否可用于帮助优化抗菌治疗疗程。
- 其他生物标志物的影响尚不明确,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Reducing the overuse of antimicrobials is imperative for the sake of minimizing antimicrobial-associated adverse effects, optimizing resource utilization, and curtailing the rise in multidrug-resistant organisms. Biomarkers reflect the host responses to infection and may assist with minimizing unnecessary antimicrobial usage. OBJECTIVES: To review the literature pertaining to the performance of biomarkers specifically used to guide the duration of antimicrobial therapy (AMT). SOURCES: Randomized controlled trials, observational studies, and meta-analyses assessing biomarker-guided approaches to AMT decision-making and their impact on the duration of therapy were reviewed. CONTENT: Several randomized controlled trials and real-world observational studies have shown that a procalcitonin (PCT)-guided strategy can help clinicians individualize the duration of AMT, particularly among non-critically ill patients hospitalized with suspected respiratory tract infections when using a PCT cut-off value of <0.25 μg/L and critically ill patients with respiratory tract infections or undifferentiated sepsis when using a PCT cut-off value of <0.5 μg/L or ≥80% decline in the peak level. C-reactive protein is a non-specific marker of inflammation that may also assist with an early discontinuation of AMT; however, data are limited. Haematological biomarkers are prone to variance between individuals and are often influenced by medications and non-infectious conditions, making them less reliable for the purposes of AMT decision-making. Novel biomarkers such as multi-protein signatures and host gene expression tests have shown promise as tools to better differentiate between bacterial and non-bacterial infections; clinical studies are needed to determine whether they can be used to help optimize the duration of AMT. IMPLICATIONS: Studies have demonstrated that a PCT-guided strategy, when utilized appropriately, can help guide clinicians to individualize and often reduce the duration of AMT, especially in patients hospitalized with respiratory tract infections and those admitted to the intensive care unit with suspected respiratory tract infections or sepsis. The impact of utilizing other biomarkers is less clear and requires further study.
引用
- Scott J, Deresinski S. Use of biomarkers to individualize antimicrobial therapy duration: a narrative review. Clin Microbiol Infect. 2022. PMID: 36096429. doi:10.1016/j.cmi.2022.08.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。